Transparency
SCP28: KEI intervention on patents and health
On 11 July 2018, Knowledge Ecology International delivered the following statement on patents and health at the 28th session of WIPO’s Standing Committee on the Law of Patents (SCP). Statement of Knowledge Ecology International Agenda item 7 – Patents and… Continue Reading
KEI comments on the prospective grant of an exclusive patent license: Mutant IDH1 inhibitors useful for treating cancer to Apexx Oncology
(Update: The NIH provided a response to our comments on August 1, 2020) July 10, 2018 Sury Vepa, Ph.D., J.D., Senior Licensing and Patenting Manager National Center for Advancing Translational Sciences National Institutes of Health Email sury.vepa@nih.gov Re: Prospective Grant… Continue Reading
NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the Treatment of Human Cancer
On July 9, 2018, KEI asked the NIH to extend the deadline for comments described on the Federal Register notice 83 FR 30448 until information about the enrollment and costs of NIH-funded clinical trials involving mesothelin expressing cancers, and trials… Continue Reading
Litigation: KEI v. NIH et al.
On April 19, 2018, KEI filed a lawsuit against the NIH license of CD30 CAR T patents to Gilead. On April 11, 2019, the lawsuit was dismissed on the grounds that KEI lacked standing. KEI blogs January 5, 2018. 2018: Briefing note… Continue Reading
WHO publishes Meeting Report of the Informal Advisory Group on the Availability and Affordability of Cancer Medicines
In May 2017, the 70th World Health Assembly passed a cancer resolution (WHA70.12, Cancer prevention and control in the context of an integrated approach). At the time KEI provided the following commentary on the cancer resolution: On Tuesday, May 30,… Continue Reading
WHA71: KEI intervention on Addressing the global shortage of, and access to, medicines and vaccines
21 May 2018 Knowledge Ecology International (KEI) intends to deliver the following statement on Addressing the global shortage of, and access to, medicines and vaccines. 11.5 Addressing the global shortage of, and access to, medicines and vaccines Documents A71/12 and… Continue Reading
Noncommunicable disease partnerships and conflicts of interest
KEI was invited to participate in the “WHO Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control,” which was held in Copenhagen, Denmark, April 9-11, 2018. A web page for the event is here. Overall,… Continue Reading
Statement of Portugal: UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030
On Tuesday, 6 March 2018, Cristina Pucarinho, the Deputy Permanent Representative of Portugal to the United Nations made the following intervention at a UN briefing on Promoting Innovation and Access to Health Technologies in the Context of the Agenda 2030… Continue Reading
KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite
KEI has appealed the NIH/NCI decision to proceed with the proposed exclusive license of anti-CD30 CAR T to Gilead, following an email of January 25, 2018 from Dr. David Lambertson of NCI rejecting all of KEI’s substantive suggestions and objections. KEI… Continue Reading